Pulmonary arterial hypertension (PAH) is a progressive, chronic disorder affecting 500 to 1,000 people annually in the U.S., often leading to delays in diagnosis and treatment.
Due to the rarity of PAH, many individuals experience an extended period of misdiagnosis, which can result in advanced disease stages by the time treatment begins.
Awareness initiatives, such as Pulmonary Hypertension Awareness Month, aim to educate the public and healthcare professionals to ensure faster recognition and management of PAH.
The collaboration between the American Lung Association and Merck demonstrates a commitment to improving patient outcomes through education about the signs, symptoms, and treatment options for PAH.
#pulmonary-arterial-hypertension #awareness-month #healthcare-education #rare-diseases #patient-advocacy
Collection
[
|
...
]